ARLINGTON, Va., May 31, 2019 /PRNewswire-PRWeb/ -- The market for liquid biopsy will near $1.6
Liquid biopsies are a set of minimally invasive diagnostic methods that analyze tumor-derived materials that can be found circulating in biological fluids, to provide information for the diagnosis, treatment, and monitoring of cancer.
Kalorama says that as of 2019, over 40 companies are active in the global market for liquid biopsy diagnostics and monitoring tests.
Liquid biopsy use will be driven by clinical demand for better tumor detection and monitoring, according to the report. Several drawbacks and limitations are associated with tissue biopsies. They are highly invasive surgical procedures that may expose patients to risks. The tumor site must be known and surgically accessible in the first place. Repeat tissue biopsies are impractical; and these surgeries are also quite costly to perform; ranging from $15K-45K.
In comparison, liquid biopsies offer several key advantages over tissue biopsies. They are less or non-invasive, lower risk, lower cost, and offer faster turnaround times for results. Moreover, liquid biopsies provide the opportunity for repeat testing, to monitor treatment progression over the course of therapy, and/or to test for recurrence after surgical removal of tumors. Liquid biopsies provide a more comprehensive picture of tumor heterogeneity, providing genomic insights for both intra-tumor, and of metastatic lesions.
Liquid biopsies, in general, are better able to capture the heterogeneity of cancer than tissue biopsies, as cells, DNA, and exosomes are shed from multiple parts of the primary tumor or metastatic lesions in various locations of the body, into the vascular and lymphatic systems. With this information, clinicians can form a more comprehensive understanding of the disease burden, and druggable variants may be identified.
There are challenges. While liquid biopsies offer many advantages, the technique is still early in its development, and pitfalls have been identified. Several studies examining tests offered by major liquid biopsy companies have found discordance between how results compare with tissue biopsy sequencing, as well as inconsistent results between various liquid biopsy assays conducted by different companies. Discrepancies and false negative results can be attributed to low occurrence of CTCs and ctDNA, akin to looking for a needle in a haystack, which makes detection difficult. However, false positive detection of biomarkers is also a common occurrence. Discrepancies may also be a product of differing assay characteristics between providers, which are difficult to assess as tests are proprietary.
Yet despite these limitations, the global market for liquid biopsy diagnostic and monitoring tests is expected to grow at a rapid pace over the forecast period of five years in the report.
Kalorama's report can be purchased here: https://kaloramainformation.com/product/the-world-liquid-biopsy-market/
SOURCE Kalorama Information
Subscribe to our Free Newsletters!